Olaparib (Lynparza®) adjuvant treatment of early breast cancer. HTA ID: 22065

Assessment Status NCPE Assessment Process Complete
HTA ID 22065
Drug Olaparib
Brand Lynparza®
Indication As monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.
Assessment Process
Rapid review commissioned 26/09/2022
Rapid review completed 20/10/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 26/10/2022
Pre-submission consultation with Applicant 13/12/2022
Full submission received from Applicant 27/09/2023
Preliminary review sent to Applicant 09/05/2024
NCPE assessment re-commenced 06/06/2024
Follow-up to preliminary review sent to Applicant 05/07/2024
NCPE assessment re-commenced 11/07/2024
Factual accuracy sent to Applicant 20/08/2024
NCPE assessment re-commenced 27/08/2024
NCPE assessment completed 24/09/2024
NCPE assessment outcome The NCPE recommends that olaparib be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations. May 2025